TY - JOUR T1 - CRISPR-Cas9 - a new addition to the drug metabolism and disposition tool box JF - Drug Metabolism and Disposition JO - Drug Metab Dispos DO - 10.1124/dmd.118.082842 SP - dmd.118.082842 AU - Maria Karlgren AU - Ivailo Simoff AU - Markus Keiser AU - Stefan Oswald AU - Per Artursson Y1 - 2018/01/01 UR - http://dmd.aspetjournals.org/content/early/2018/08/20/dmd.118.082842.abstract N2 - Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR associated protein 9 or CRISPR-Cas9 has been extensively used as a gene-editing technology during recent years. Unlike earlier technologies for gene-editing or gene knockdown, such as zinc finger nucleases and RNAi, CRISPR-Cas9 is comparably easy to use, affordable and versatile. Recently CRISPR-Cas9 has been applied in studies of drug absorption, disposition, metabolism and excretion (ADME) and for ADME model generation. Today about 50 papers have been published describing in vitro or in vivo CRISPR-Cas9 gene-editing of ADME and ADME-related genes. Twenty of these papers describe gene-editing of clinically relevant genes, such as ABC drug transporters and CYP drug metabolizing enzymes. With CRISPR-Cas9, the ADME tool box has been substantially expanded. This new technology allows us to develop better and more predictive in vitro and in vivo ADME models and map previously underexplored ADME genes and gene families. In this mini-review we give an overview of the CRISPR-Cas9 technology and summarize recent applications of CRISPR-Cas9 within the ADME field. We also speculate about future applications of CRISPR-Cas9 in ADME research. ER -